secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVANOS MEDICAL, INC. (AVNS)
CIK:        0001606498
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001606498-25-000126
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avanos eliminates Chief Commercial Officer and General Counsel positions; two executives to leave Dec 1
--------------------------------------------------------------------------------

- Kerr Holbrook (CCO) and Mojirade James (General Counsel & Secretary) terminated effective Dec 1, 2025 due to position elimination in restructuring.
- Severance: Holbrook ~$1.54M, James ~$1.43M, plus 12 months COBRA premium coverage.
- Unvested equity: time-based RSUs vest pro rata; performance-based RSUs vest at end of period; stock options exercisable for 5 years.
- Prorated 2025 bonuses at target approved for both executives.
- Payments conditional on separation agreement, general release, and continued compliance with confidentiality/non-solicitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000126/0001606498-25-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1606498/000160649825000126/avns-20251021.htm
  HTML page:      https://secwatch.observer/filing/0001606498-25-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer